NTRA vs VCYT
NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications. VCYT: Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
Side-by-side fundamentals
| Metric | NTRA | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $390.79 | $43.60 | |
| Market cap | $56.3B | $3.5B | |
| P/E as of 2026-10-08 | n/a | 31.08 | |
| Net margin FY2025, SEC XBRL | -9.0% | +12.8% | VCYT higher |
| Gross margin FY2025, SEC XBRL | n/a | +70.1% | |
| Operating margin FY2025, SEC XBRL | -13.4% | +11.2% | VCYT higher |
| ROE FY2025, SEC XBRL | -12.2% | +5.1% | VCYT higher |
| ROA FY2025, SEC XBRL | -8.7% | +4.7% | VCYT higher |
| Debt / equity as of 2026-09-03 | 0.04 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-09-03 | +37.8% | +17.3% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +20.4% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.29 | 1.32 | |
| 1-year return as of 2026-10-08 close | +127.1% | +24.2% | NTRA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.